Osteitis Deformans (Paget's Disease of Bone)

A disease marked by repeated episodes of increased bone resorption followed by excessive attempts at repair, resulting in weakened, deformed bones of increased mass. The resultant architecture of the bone assumes a mosaic pattern in which the fibers take on a haphazard pattern instead of the normal parallel symmetry.

Also Known As:

Networked: 661 relevant articles (56 outcomes, 62 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Bone Resorption
2.	Osteoporosis
3.	Neoplasm Metastasis (Metastasis)
4.	Hypercalcemia (Milk Alkali Syndrome)
5.	Neoplasms (Cancer)

Experts

1.	Kimonis, Virginia E: 20 articles (05/2015 - 03/2002)
2.	Nalbandian, Angèle: 12 articles (05/2015 - 01/2010)
3.	Ralston, Stuart H: 12 articles (07/2014 - 10/2002)
4.	Layfield, Robert: 11 articles (07/2014 - 09/2003)
5.	Searle, Mark S: 8 articles (07/2014 - 09/2003)
6.	Llewellyn, Katrina J: 7 articles (05/2015 - 01/2012)
7.	Vesa, Jouni: 6 articles (05/2015 - 01/2010)
8.	Nguyen, Christopher: 6 articles (01/2015 - 11/2011)
9.	Devogelaer, Jean-Pierre: 6 articles (03/2014 - 01/2002)
10.	Walsh, John P: 6 articles (08/2013 - 02/2005)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Osteitis Deformans:

1.	DiphosphonatesIBA 10/01/1996 - "The potent bisphosphonates offer great promise in the management of Paget's disease of bone, but are currently available only as parenteral preparations in most countries. " 02/01/1995 - "Bisphosphonates have been shown to be effective in suppressing the elevated bone turnover found in Paget's disease of bone. " 12/01/1991 - "Bisphosphonates have been shown to be effective in treating the increased bone turnover associated with Paget's disease of bone. " 01/01/2009 - "Although daily doses of oral bisphosphonates are a generally safe and effective treatment for Paget's disease of bone (PDB), some patients may experience upper gastrointestinal adverse events (UGI AEs) or find the dosing requirements inconvenient and become noncompliant. " 12/01/1993 - "Bisphosphonates are a safe and effective treatment for Paget's disease of bone, but little information is available about the factors influencing the duration of remission so obtained. "
2.	pamidronate (APD)FDA LinkGeneric 03/01/1994 - "The efficacy of five therapeutic regimens using (3-amino-1-hydroxypropylidene)-1,1- bisphosphonate (APD or pamidronate) was assessed in patients with Paget's disease of bone. " 10/01/1993 - "Pamidronate is effective for Paget's disease of bone refractory to conventional therapy." 12/01/1991 - "These data confirm that pamidronate is effective in the management of Paget's disease of bone. " 07/01/1993 - "Pamidronate treatment in patients with Paget's disease of bone is effective and safe." 10/10/2003 - "To determine the efficacy of pamidronate disodium (pamidronate) in treatment of Paget's disease of bone. "
3.	Etidronic Acid (HEDP)FDA LinkGeneric 04/01/1983 - "EHDP (5 mg/kg/day) can be regarded as effective treatment for some patients with Paget's disease of bone." 01/01/1981 - "Histologically, EHDP given at a dose of 5 mg/kg/day for 6 months appears to be an effective and safe treatment for Paget's disease of bone." 01/01/1981 - "Studies regarding the efficacy of EHDP in the treatment of Paget's disease of bone conducted at our institution are described. " 11/01/1985 - "A long-term trial of etidronate disodium therapy in 93 patients with Paget's disease of bone yielded generally favorable results. " 01/01/1977 - "On the basis of the biochemical and clinical data in this study it appears that initial therapy of Paget's disease of bone with 5 mg EHDP/kg/day maximizes benefits while minimizing possible adverse effects."
4.	zoledronic acid (zoledronate)FDA Link 01/01/2007 - "Thus, zoledronic acid is an important first-line treatment for Paget's disease of bone." 01/01/2011 - "Zoledronic acid-induced transient hepatotoxicity in a patient effectively treated for Paget's disease of bone." 10/01/2015 - "ZOLEDRONIC ACID THERAPY OF PATIENTS WITH PAGET DISEASE OF BONE RESISTANT TO OR WITH UNSUSTAINED REMISSION FOLLOWING PRIOR BISPHOSPHONATE THERAPY." 09/01/2014 - "We recommend zoledronic acid in the first-line treatment of Paget disease of bone in achieving and maintaining remission." 09/01/2014 - "Efficacy of zoledronic acid treatment in Paget disease of bone."
5.	risedronic acid (risedronate)FDA LinkGeneric 02/01/1999 - "In conclusion, risedronate administered at daily doses of 10, 20, and 30 mg for 28 days was effective in reducing the biochemical indices of disease activity in patients with severe Paget's disease of bone. " 07/01/2010 - "This study evaluated the clinical efficacy of treatment with oral risedronate (17.5 mg once daily) for 8 weeks in 11 Japanese patients with Paget's disease of bone (PDB). " 09/01/2015 - "Clinical efficacy of oral risedronate therapy in Japanese patients with Paget's disease of bone." 07/01/1997 - "To study changes in bone mineral density (BMD) in patients with Paget's disease of bone treated with risedronate. " 02/01/2013 - "Midterm outcome of risedronate therapy for patients with Paget's disease of bone in the central part of Japan."
6.	Calcitonin (Calcitonin, Eel)FDA LinkGeneric 04/01/1981 - "The efficacy of calcitonin in the treatment of Paget's disease of bone is well established, especially as it is currently the most effective agent in the treatment of the osteolytic form of the disease. " 11/05/1977 - "Calcitonin appears to be effective initially in most patients with Paget's disease of bone, but with long-term treatment resistance may be acquired." 01/29/1977 - "It is concluded that human calcitonin is beneficial in the treatment of Paget's disease of bone and may prevent the problems of antibody resistance and allergic phenomena encountered with other preparations of calcitonin." 09/01/1981 - "We conclude that synthetic human calcitonin is a safe and effective treatment for Paget's disease of bone. " 02/01/1983 - "Numerous studies have been done to determine the effects of long term calcitonin (CT) treatment on Paget's disease of bone, but very few studies have been undertaken to determine the long term CT effect on nonpagetic bone in man. "
7.	Alendronate (Alendronate Sodium)FDA LinkGeneric 03/01/1997 - "We conclude that oral alendronate is an effective agent for the treatment of Paget's disease of bone." 10/01/1996 - "Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial." 03/01/2008 - "Our recent observations in 2 elderly women with inactive monostotic Paget's disease of bone who had been treated elsewhere continuously for this disease with alendronate for 10 yr at doses overall of 2 and 4 times the osteoporotic dose provided an opportunity to engage in the ongoing controversy over long-term safety of bisphosphonate therapy. " 01/01/2005 - "Low dose of oral alendronate decreases bone turnover in Japanese patients with Paget's disease of bone." 05/01/1999 - "Treatment of Paget's disease of bone with alendronate."
8.	tiludronic acid (tiludronate)FDA Link 08/01/1997 - "A double-blind, multicentre, placebo-controlled study of tiludronate in Paget's disease of bone." 11/01/1995 - "The methodology of clinical trials of oral tiludronate in Paget's disease of bone." 11/01/1995 - "A double-blind, randomized, placebo-controlled study was performed to evaluate the effect of oral tiludronate therapy in 139 patients with active Paget's disease of bone. " 01/01/2002 - "Results for these women were compared with those of 29 patients with Paget's disease of bone treated with tiludronate (400 mg/day) for 3 months, and with those of a group of 21 healthy premenopausal women (control group I). " 09/01/1997 - "Comparison of the efficacy and bioequivalence of two oral formulations of tiludronate in the treatment of Paget's disease of bone."
9.	PlicamycinFDA Link 01/01/1980 - "Mithramycin and long remission of Paget's disease of bone." 10/01/1980 - "Mithramycin treatment of Paget's disease of bone. " 03/01/1979 - "Long term effectiveness of low dose mithramycin for Paget's disease of bone." 11/01/1974 - "Outpatient treatment of Paget's disease of bone with mithramycin." 06/09/1973 - "Mithramycin in Paget's disease of bone."
10.	6- amino- 1- hydroxyhexane- 1,1- diphosphonateIBA 10/01/2009 - "In Paget's disease of bone, 200 mg intravenous neridronic acid is associated with a 65% rate of full remission and a biochemical response (decrease of > 75% of bone turnover markers) in 95% of the patients. " 03/01/2011 - "Comparison of intravenous and intramuscular neridronate regimens for the treatment of Paget disease of bone." 12/01/1998 - "This study assessed the efficacy of 200 mg of aminohexane bisphosphonate (neridronate) administered by intravenous infusion in a single dose or in two separate doses on consecutive days in 32 patients (16 males and 16 females, average age 66 years) affected by active Paget's disease of bone. " 01/01/2002 - "To describe the effects of two consecutive intravenous infusions of aminohexane bisphosphonate (Neridronate) in patients with active Paget's disease of bone. " 01/01/2013 - "Neridronate is an aminobisphosphonate, licensed in Italy for the treatment of osteogenesis imperfecta (OI) and Paget's disease of bone (PDB). "

Therapies and Procedures

1.	Intravenous Infusions 05/01/1990 - "This study examined the effects of aminohydroxybutylidene bisphosphonate in 30 patients with Paget's disease of bone, administered as an intravenous infusion for 5 consecutive days. " 12/05/1992 - "Pamidronate disodium (APD) given as a single 60 mg intravenous infusion over 24 hours was shown to be an effective treatment for Paget's disease of bone. " 12/01/1998 - "This study assessed the efficacy of 200 mg of aminohexane bisphosphonate (neridronate) administered by intravenous infusion in a single dose or in two separate doses on consecutive days in 32 patients (16 males and 16 females, average age 66 years) affected by active Paget's disease of bone. " 03/01/2014 - "Using data from the Belgian Paget's Disease Registry of 142 patients treated with a 5 mg intravenous infusion of zoledronic acid, we examined disease remission over 3 years in 98 patients with Paget disease of bone (PDB) seen in routine practice. " 03/01/2014 - "Remission over 3 years in patients with Paget disease of bone treated with a single intravenous infusion of 5 mg zoledronic acid."
2.	Aftercare (After-Treatment) 10/01/1999 - "Patients with active Paget's disease of bone are characterized by an abnormally high alpha/beta-CTX ratio which goes down to the normal range after bisphosphonate therapy, probably reflecting the lamellar structure of newly formed bone matrix in pagetic skeletal sites after treatment." 06/01/1981 - "The value of bone scintigraphy in the prediction and detection of a relapse of Paget's disease of bone after treatment, as well as the pattern of such a recurrence, were studied in a group of 40 patients. " 07/01/2015 - "The aim of this systematic review and meta-analysis is to study the utility of the commonly used bone turnover markers in evaluating disease activity in patients with Paget's disease of bone before and after treatment with bisphosphonates. " 04/01/2010 - "Dual-energy X-ray absorptiometry and quantitative ultrasound in patients with Paget's disease of bone before and after treatment with zoledronic acid: association with serum bone markers and Dickkopf-1." 03/01/1992 - "We measured BPS in 36 patients with Paget's disease of bone, both before and 6 months after treatment with intravenous APD (disodium pamidronate) infusions. "
3.	Arthroplasty 12/01/2010 - "Cementless total hip arthroplasty in Paget's disease of bone: a retrospective review." 09/01/2005 - "Total knee arthroplasty in patients with Paget's disease of bone at the knee." 06/01/1991 - "Total knee arthroplasty for osteoarthrosis in patients who have Paget disease of bone at the knee."
4.	Retreatment 06/29/1985 - "Intravenous clodronate in the treatment and retreatment of Paget's disease of bone." 12/01/1998 - "We conclude that neridronate can be used safely in the treatment of patients with Paget's disease of bone either as a first bisphosphonate treatment or as retreatment for patients relapsing after clodronate."
5.	Radiotherapy 08/01/1979 - "Radiotherapy is contraindicated, since bone affected by osteitis deformans may possibly become malignant." 02/01/1970 - "The treatment of Paget's disease of bone by radiotherapy."